Rosh Psychiatry Board Practice Exam

Fluoxetine is recognized as a first-line treatment for mild to moderate body dysmorphic disorder (BDD). This selectivity is rooted in its classification as a selective serotonin reuptake inhibitor (SSRI), which has been shown to be effective in alleviating symptoms of various obsessive-compulsive disorders, including BDD.

Numerous studies and clinical guidelines support the use of SSRIs for BDD management due to their ability to modify the underlying neurochemical imbalances associated with the disorder. Patients with BDD may experience intrusive thoughts and behaviors relating to perceived flaws in their appearance, which can lead to significant distress and impairment. The use of fluoxetine not only helps in reducing anxiety and compulsive behaviors but also improves overall mood and functioning in these individuals.

While other medications may address different mental health concerns, fluoxetine’s specific efficacy in treating the symptoms of body dysmorphic disorder makes it the preferred choice in this context.